A bill for an act relating to liability for injuries caused by vaccines.
Summary
HF 2287 would change Iowa law governing vaccine liability by conditioning the distribution, sale, or administration of a vaccine in the state on the manufacturer’s waiver of immunity from suit for injuries arising from a design defect. The bill specifically targets immunity under the federal National Childhood Vaccine Injury Act and states that a vaccine may not be distributed in Iowa unless the manufacturer affirmatively waives that protection.
The bill also creates a new state-law provision deeming a vaccine manufacturer to have waived immunity for design-defect injuries if the vaccine is distributed, sold, or administered in Iowa. In practical terms, this would expose manufacturers to state-court product liability claims for alleged design defects, despite existing federal immunity protections, and could affect vaccine availability, distribution decisions, and litigation risk for manufacturers and providers operating in Iowa.
Impact
HF 2287 would add two new sections to Iowa law, one limiting vaccine distribution and one creating a waiver-of-immunity rule for vaccine injury claims. It would directly affect vaccine manufacturers, distributors, sellers, and administrators in Iowa by making market access contingent on surrendering immunity from design-defect lawsuits. The bill would also intersect with federal vaccine injury law, particularly the National Childhood Vaccine Injury Act, by attempting to override or bypass the immunity it provides.
Sentiment
The available legislative history suggests the bill had at least some support at the subcommittee level, as the last recorded action was a subcommittee recommendation for passage. No vote totals or committee transcript excerpts are provided, so the broader level of support or opposition cannot be measured from the record here. Based on the bill’s subject matter, it appears to have been treated as a serious liability and consumer-protection measure rather than a routine technical change.
Contention
The central point of contention is the bill’s attempt to eliminate or condition federal and state immunity for vaccine manufacturers, which would likely draw opposition from manufacturers, public health stakeholders, and others concerned about vaccine access and the interaction with federal law. Supporters would likely frame the bill as expanding accountability and allowing injured parties to pursue design-defect claims. The main dispute is therefore between those prioritizing legal remedies for vaccine injuries and those warning that the measure could conflict with federal protections and discourage vaccine distribution in Iowa.